Precigen Inc PGEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
-
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices
-
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
-
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States
-
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference
-
Precigen Reports First Quarter 2026 Financial Results and Business Updates
-
Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13
-
Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million
Trading Information
- Previous Close Price
- $4.75
- Day Range
- $4.72–4.89
- 52-Week Range
- $1.39–5.47
- Bid/Ask
- $4.85 / $4.86
- Shares Outstanding
- 356.51M
- Market Cap
- $1.74B
- Volume/Avg
- 1M / 5M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 46.21
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.08%
Company Profile
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 47
- Website
- http://www.precigen.com
Valuation
|
Metric
|
PGEN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 78.27 |
Price/Sales | 46.21 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PGEN
|
|---|---|
Quick Ratio | 3.93 |
Current Ratio | 4.82 |
Interest Coverage | −29.62 |
Quick Ratio
PGEN
Profitability
|
Metric
|
PGEN
|
|---|---|
Return on Assets (Normalized) | −76.93% |
Return on Equity (Normalized) | −1,664.39% |
Return on Invested Capital (Normalized) | −154.24% |
Return on Assets
PGEN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Cnjyctmgc | Pwxznmn | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Npywtxcr | Zgdlw | $64B | |||
| argenx SE ADR
ARGX
| Qcssctkl | Fwdn | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Svzfwcgl | Mlrxyp | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Pclcdrwhk | Lsvlrl | $24B | |||
| BioNTech SE ADR
BNTX
| Ccllcjlg | Dmcbc | $23B | |||
| Incyte Corp
INCY
| Wldbpqph | Myv | $22B | |||
| Moderna Inc
MRNA
| Tftybkfs | Dxz | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Tktmrjlt | Qknl | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Ltvvgjyx | Gjq | $13B |
United States